Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stopped Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.

Conditions

• Breast Cancer
• Lung Cancer
• Pulmonary Cancer
• Non-Small-Cell Lung Carcinoma
• Prostate Cancer
• Prostatic Cancer
• Gastric Cancer
• Stomach Cancer

Interventions

• DRUG: MGCD0103 & Docetaxel

Sponsor

Mirati Therapeutics Inc.